CA-JUNIPER-NETWORKS
14.7.2021 09:02:09 CEST | Business Wire | Press release
Juniper Networks , (NYSE: JNPR) a leader in secure, AI-driven networks, announced today that CMC Networks, a global service provider offering market-leading networking solutions, is the first Juniper partner to offer a managed AI-driven SD-WAN solution in Africa. A dynamic and self-optimizing network will deliver a superior experience to CMC’s customers, allowing them to easily modify their services, add new locations and spin up and down network speeds. Time-to-market is significantly reduced, enabling CMC to provision services faster.
By leveraging Juniper’s unique Session Smart® Router technology driven by Mist AI, CMC is delivering a unique tunnelless solution that is designed for scale and agility, coupled with automated provisioning, management and troubleshooting for maximum uptime, superior performance of real-time traffic and lower operating costs in both rural and urban environments.
News highlights:
- CMC chose the Session Smart Router and standardized on Juniper’s STEP (Service and Topology Exchange Protocol) in order to navigate network traffic with real-time data information. This allows accurate and immediate decision making autonomously, minimizing delays to ensure that network traffic arrives at its destination in the most efficient way possible. This helps to ensure that CMC’s customers receive a SD-WAN service that is high-performing, secure and reliable.
- The Juniper solution includes Secure Vector Routing (SVR), a transformational new intelligent routing architecture that enables CMC’s network to differentiate the way it delivers applications and services to end users. The SVR allows a network to identify problems and automatically decide the most effective path to re-route traffic. This supports business applications without user intervention, in support of the best possible user experience.
- The Juniper® Session Smart Router (SSR) fuels an advanced, service-centric networking solution and Mist AI engine that takes software-defined routing and SD-WAN to a new level. The SSR enables agile, secure, and resilient WAN connectivity. With tunnelless SSR technology, each session is secured with zero trust access by default, providing the highest level of security. Additionally, eliminating tunnel overhead increases bandwidth capacity and enables an improved user experience.
- CMC has been rolling out Session Smart Routers in Africa for the last three years, leveraging the organization’s scale and footprint to enable digital transformation across the region. In the future, the company plans to broaden its footprint into additional regions and deliver even more AI-driven managed services powered by Juniper, including wireless access.
- CMC is in the process of planning the rollout of additional cloud-hosted services driven by Mist AI, including WAN Assurance and the Marvis™ Virtual Network Assistant . These further streamline the deployment, operations and troubleshooting of its AI-driven SD-WAN environment with zero touch provisioning, customizable service levels, self-driving operations and AI-driven support to proactively address problems before customers even know they exist.
Supporting Quotes:
“SD-WAN is not a new technology and every SD-WAN player gives customers speed and power on the network. However, digital transformation strategies require a high level of intelligence, support and the ability to underpin business-critical applications - attributes that many SD-WAN vendors can’t provide. Juniper’s AI-driven SD-WAN gives CMC a level of intelligence and operational insight that we haven’t seen before.”
Geoff Dornan, Chief Technology Officer, CMC Networks
"Juniper’s AI-driven SD-WAN solution, powered by our Session Smart Router and Mist AI, enables us to be laser-focused on optimizing user experience. We recognized early that networks must be application-aware to support the demands of the evolving enterprise and to deliver the highest levels of user experience. Juniper ticks all the necessary boxes by delivering on the promise of a truly intelligent network that adapts as user requirements change. Juniper is thrilled that our innovative work with CMC has yielded this much-needed solution to enable consistent and excellent user experiences, even in the most challenging geographies, and we look forward to continued collaboration."
Sue Graham Johnston, Vice President and General Manager, Juniper Networks
Additional Resources:
CMC Networks: Connecting African & Middle Eastern Communities with Secure, Reliable SD-WAN (video)
About Juniper Networks
Juniper Networks is dedicated to dramatically simplifying network operations and driving superior experiences for end users. Our solutions deliver industry-leading insight, automation, security and AI to drive real business results. We believe that powering connections will bring us closer together while empowering us all to solve the world’s greatest challenges of well-being, sustainability and equality. Additional information can be found at Juniper Networks (www.juniper.net ) or connect with Juniper on Twitter , LinkedIn and Facebook .
Juniper Networks, the Juniper Networks logo, Juniper, Junos, and other trademarks listed here are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.
Category-Service Provider
View source version on businesswire.com: https://www.businesswire.com/news/home/20210714005023/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
